This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Frei, B. L. Articles by Soefje, S. A. Search for Related Content Social Bookmarking                         What's this?

A Review of the Cardiovascular Effects of Oncology Agents

University of the Incarnate Word, Feik School of Pharmacy, Department of Pharmacy Practice, frei@ uiwtx.edu

Scott A. Soefje, PharmD, BCOP

Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio San Antonio, Texas

Cardiovascular toxicity is an important adverse effect of several classes of oncology drugs. Because cancer survivors are living longer, the late effects of cancer therapy must be addressed. Many patients diagnosed with cancer are already at an increased risk for cardiovascular disease before drug treatment. Select chemotherapy agents further complicate the issue because of their own ability to induce cardiovascular toxicities or exacerbate preexisting conditions. Hypertension, dyslipidemia, heart failure, and arrhythmia are known consequences of some cancer therapies. This review provides an overview of the epidemiology, mechanism of action, monitoring, and management of these cardiovascular effects.

Key Words: antineoplastic agents • hypertension • dyslipidemia • congestive heart failure • arrhythmia

Journal of Pharmacy Practice, Vol. 21, No. 2, 146-158 (2008)
DOI: 10.1177/0897190008314776


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?